Technology-based Company.

Engaged in advancing innovative solutions for large-scale market applications

Medigus and HC Marbella International Hospital Announce First Muse™ Procedure

OMER, Israel, and Marbella, Spain, April 17, 2018 – Medigus Ltd. (NASDAQ: MDGS) (TASE: MDGS), a medical device company developing minimally invasive endosurgical tools and an innovator in direct visualization technology, along with High Care Marbella International Hospital, today announced the completion of the first MUSE procedure in Spain. The procedure was performed by Dr. Victor Aguilar at HC Marbella International Hospital. Dr. Aguilar reported that the procedure was successful and the patient was released from the hospital.

“It’s extremely exciting to see Dr. Aguilar pioneer the procedure in another key market for the MUSE system,” said Chris Rowland, Chief Executive Officer of Medigus. “We are looking to build on the physician interest of the MUSE procedure at Marbella, and expand availability in other areas of Europe in the future.”

The MUSE system is a single-use flexible transoral stapler that merges the latest advancement in microvisual, ultrasonic and surgical stapling. The device comes equipped with an ultrasonic sight and range finder and a micro ScoutCam™ CMOS camera, which enables a single physician to perform an incisionless transoral fundoplication, the procedure intended to treat the anatomical cause of gastroesophageal reflux disease (GERD). As the device requires no incisions, patients generally report greater comfort during the procedure and experience reduced hospital stays by up to 50% over invasive fundoplication procedures.

“With about fifteen percent of Spain’s population experiencing GERD on a weekly basis , I am pleased to lead a procedure that is addressing a long time need,” said Dr. Aguilar. “The MUSE system enables me to bring the benefits of an incision-less procedure for GERD patients as an alternative to drug therapy and invasive surgical procedures.”

Those who experience symptoms such as heartburn or regurgitation twice a week or more, may be at risk for persistent GERD.

About Medigus

Medigus is a medical device company specializing in developing minimally invasive endosurgical tools and highly innovative imaging solutions. They are the pioneer developer of the MUSE™ system, an FDA cleared and CE marked endoscopic device to perform Transoral Fundoplication (TF) for the treatment of GERD (gastroesophageal reflux disease), one of the most common chronic conditions in the world. In 2016, the CMS established the Category I CPT® Code of 43210 for TF procedures, such as the ones performed with MUSE, which establishes reimbursement values for physicians and hospitals. MUSE is gaining adoption in key markets around the world – it is available in world-leading healthcare institutions in the U.S., Europe and Israel. Medigus is also in the process of obtaining regulatory clearance in China. Medigus is traded on the Nasdaq Capital Market and the TASE (Tel-Aviv Stock Exchange). To learn more about the company’s advanced technology, please visit www.medigus.com or www.RefluxHelp.com.

About HC Marbella International Hospital

HC Marbella International Hospital is an exclusive private hospital delivering high quality medical care located in Costa del Sol.

Web: www.hcmarbella.com

To learn more about Dr. Aguilar: www.vitalidaddigestiva.com